Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023890 (
cirrhosis
)
42,195
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A new operation for selective or total decompression of the portal venous system in cases of intrahepatic portal hypertension is described. It involves interposition of a large-caliber Dacron graft between the splenic vein and the inferior vena cava. The graft-interposition splenocaval shunt is performed readily and quickly, satisfying the variable hemodynamic needs of patients with portal hypertension. It can be either selective (S-
SCS
) or total (T-
SCS
) from the beginning, or a T-
SCS
may be converted subsequently to a S-
SCS
should surgically induced hepatic decompensation supervene. It is less demanding technically than distal splenorenal shunt (D-SRS). The S-
SCS
conserves portal venous perfusion of the liver, preserves hepatocellular function and architecture at the preoperative levels, avoids precipitation of postshunt portal-systemic encephalopathy, and decompresses gastric-esophageal varices with prevention of further variceal bleeding even better than D-SRS. One hundred percent graft patency has been obtained, and the surgical results have been superior to those following portacaval shunt in patients with large liver blood flow and relative benignity of the liver disease, be it
cirrhosis
or noncirrhotic portal fibrosis. In patients with advanced
cirrhosis
, variceal bleeding, and small liver blood flows, T-
SCS
would be indicated. Patients of this category obtained inferior surgical results and had operative deaths (16.7%) following S-
SCS
. The concept of the operation has merits and deserves further evaluation.
...
PMID:Graft interposition splenocaval shunt for total or selective decompression of portal hypertension. 62 91